




# Letermovir

your ccure api by **Lebsa** and **Selectchemie**



Main Therapeutic Application

**ANTIVIRAL**

CAS-RN	917389-32-3
Specification	In House
Documentation	Under Development

Letermovir (CAS-RN 917389-32-3) is an antiviral agent approved in 2017 by US FDA to be used in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Designated an orphan drug by FDA for prevention of CMV viremia and disease in at-risk populations.

let us cure together

Cta. de l'Hospitalet, 34,  
08940 Cornellà (Barcelona)  
+34 93 377 00 51  
lebsa@lebsa.com  
www.lebsa.com



**Selectchemie**

Etzelstrasse, 42,  
P.O. Box 772, CH-8038 Zürich  
+41 44 487 96 11  
info@selectchemie.com  
www.selectchemie.com

Africa, Asia,  
Australia, Canada,  
Russia, USA.

Europe (except Russia),  
LATAM, Brasil, Morocco,  
Bangladesh, Egypt.